Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 8:12:19.
doi: 10.5334/tohm.695. eCollection 2022.

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents

George T Kannarkat  1   2 , Stanley N Caroff  3 , James F Morley  1   2
Affiliations
Review

Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents

George T Kannarkat et al. Tremor Other Hyperkinet Mov (N Y). .

Abstract

Background: The last decade has seen development of numerous novel antipsychotic drugs with unique mechanisms including long-acting formulations for clinical use. A comparative assessment of these new drugs with each other and previous antipsychotics have not been performed with regards to risk for drug-induced movement disorders (DIMD).

Methods: Medline was searched from January 2010 to February 2022 for primary research articles and review articles in English using the search terms "extrapyramidal" and "tardive" with individual drug names of novel antipsychotics.

Results: We identified articles describing the risk of DIMD with 6 novel antipsychotics, 4 novel formulations, and 3 experimental antipsychotics. Both short- and long-term data generally showed comparable to lower risk of DIMD with novel antipsychotics and recent long-acting formulations compared to previously marketed antipsychotics.

Discussion: Several novel antipsychotics, particularly lumateperone and pimavanserin, show promise in being able to treat psychosis while reducing the risk of DIMD. Long-acting paliperidone may reduce risk of DIMD while other long-acting injectable formulations of SGA have similar risk of DIMD compared to oral formulations. New drug targets for treating psychosis without dopamine blockade also show promise.

Keywords: antipsychotics; drug-induced movement disorders; drug-induced parkinsonism; neuroleptic; tardive syndromes.

PubMed Disclaimer

Conflict of interest statement

Dr. George T. Kannarkat serves as a consultant for Guidepoint Global. Dr. Stanley Caroff served as consultant for Neurocrine Biosciences and Adamas Pharmaceuticals and received research grants from Neurocrine Biosciences and Eagle Pharmaceuticals unrelated to the current manuscript. Dr. James Morley has served as a consultant to GE Healthcare and received funding from the Department of Defense and the Department of Veteran Affairs unrelated to this review.

References

    1. Hauser RA, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2020; 1–10. DOI: 10.1017/S109285292000200X - DOI - PMC - PubMed
    1. Factor SA, et al. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol. 2019; 18: 880–890. DOI: 10.1016/S1474-4422(19)30152-8 - DOI - PubMed
    1. Caroff SN, Campbell EC. Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice. Psychiatr. Clin. North Am. 2016; 39: 391–411. DOI: 10.1016/j.psc.2016.04.003 - DOI - PubMed
    1. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J. Clin. Psychiatry. 2017; 78; e264–e278. DOI: 10.4088/JCP.16r10832 - DOI - PubMed
    1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004; 161: 414–425. DOI: 10.1176/appi.ajp.161.3.414 - DOI - PubMed

MeSH terms

Substances